MedTrace Logo

Coherent Sine Burst (CSE) Electroporation System Pilot Study in Patients With Atrial Fibrillation

NCT05572047 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-12-05

No results posted yet for this study

Summary

To evaluate the safety and efficiency of the Arga Medtech CSE Ablation System in the treatment of atrial fibrillation.

Conditions

Interventions

DEVICE

Arga Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System

Use of coherent sine-burst electroporation to ablate paroxysmal and persistent AF

Sponsors & Collaborators

  • Arga Medtech SA

    lead INDUSTRY

Principal Investigators

  • Ante Anic, MD · University Hospital of Split

  • Giorgi Papiashvili · Israeli-Georgian Medical Research Clinic Helsicore

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-11
Primary Completion
2026-04-30
Completion
2026-06-30
FDA Device
Yes

Countries

  • Croatia
  • Georgia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05572047 on ClinicalTrials.gov